Shares of AbbVie (ABBV) were up Friday after the company reported a big jump in revenue. The drug maker said revenue rose to $6.45 billion, the increase driven by the demand for Humira. Earnings of $1.26 a share topped analysts' predictions. The company expects full-year earnings in the range of $4.73 to $4.83 per share, which is higher than the previous guidance outlook. AbbVie shares have climbed more than nine percent since the beginning of the year.
More from Video
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.
AMSC CEO discusses that and China challenges.